Efficacy of rituximab in refractory neuromyelitis optica

被引：49

作者：

Collongues, N. ^{[1
]}

Brassat, D. ^{[2
]}

Maillart, E. ^{[3
]}

Labauge, P. ^{[4
]}

Ouallet, J. C. ^{[5
]}

Carra-Dalliere, C. ^{[4
]}

Moreau, T. ^{[6
]}

Bourre, B. ^{[7
]}

Papeix, C. ^{[3
]}

Brochet, B. ^{[5
]}

Audoin, B. ^{[8
]}

Vukusic, S. ^{[9
]}

de Seze, J. ^{[1
]}

Marignier, R. ^{[9
]}

机构：

[1] Hop Hautepierre, Dept Neurol, 1 Ave Moliere, F-67200 Strasbourg, France

[2] Hop Purpan, Dept Neurol, Toulouse, France

[3] Hop La Pitie Salpetriere, Dept Neurol, Paris, France

[4] Hop Univ Montpellier, Dept Neurol, Montpellier, France

[5] Ctr Hosp Univ Bordeaux, Dept Neurol, Bordeaux, France

[6] Hop Univ Dijon, Dept Neurol, Dijon, France

[7] Hop Charles Nicolle, Dept Neurol, Rouen, France

[8] Hop Univ Marseille, Dept Neurol, Marseille, France

[9] Hosp Civils Lyon, Hop Neurol Pierre Wertheimer, Dept Neurol, Lyon, France

来源：

MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷 / 07期

关键词：

Neuromyelitis optica; rituximab; refractory; disability; body mass index; CHINESE PATIENTS; RELAPSE;

D O I：

10.1177/1352458515602337

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background: Despite a growing use of rituximab (RTX) in neuromyelitis optica (NMO), data are lacking in patients with refractory NMO (RNMO), defined as cases with at least one relapse during immunosuppressive therapy. Objective: The purpose of this study was to assess RTX as a maintenance therapy in RNMO. Methods: Out of a total of 305 NMO cases from a population-based cohort, 21 RNMO patients received RTX during a mean follow-up period of 31 months. Results: After RTX, 11 patients (52.3%) were relapse free, meaning that 47.7% were refractory to RTX. The mean annualized relapse rate decreased from 1.3 to 0.4 (p<0.001) and median EDSS from 5 to 3 (p=0.02). Body mass index (BMI) was predictive of EDSS worsening. Conclusions: RTX is an effective and well-tolerated treatment in RNMO. BMI could be a predictive factor for efficacy.

引用

页码：955 / 959

页数：5

共 50 条

[1] Efficacy of rituximab in refractory neuromyelitis optica
Collongues, N.
Brassat, D.
Maillart, E.
Labauge, P.
Ouallet, J. -C.
Carra-Dalliere, C.
Moreau, T.
Bourre, B.
Papeix, C.
Audoin, B.
Brochet, B.
Vukusic, S.
De Seze, J.
Marignier, R.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 78 - 79
[2] Efficacy of rituximab in refractory neuromyelitis optica
Collongues, N.
Brassat, D.
Maillart, E.
Labauge, P.
Ouallet, J. -C.
Dalliere, C. Carra
Moreau, T.
Bourre, B.
Papeix, A. -C.
Audouin, B.
Brochet, B.
Vukusic, S.
De Seze, J.
Marignier, R.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 86 - 86
[3] Outcome of rituximab therapy in refractory neuromyelitis optica
Kurian, Sonu
Marimuthu, Jawahar
[J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
[4] Efficacy and Safety of Rituximab in Pediatric Neuromyelitis Optica
Mahmood, Naznin A.
Silver, Kenneth
Onel, Karen
Ko, Michael
Javed, Adil
[J]. JOURNAL OF CHILD NEUROLOGY, 2011, 26 (02) : 244 - 247
[5] Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence
Etemadifar, Masoud
Salari, Mehri
Mirmosayyeb, Omid
Serati, Mehdi
Nikkhah, Roham
Askari, Mozhde
Fayyazi, Emad
[J]. JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2017, 22
[6] Safety and efficacy of rituximab in neuromyelitis optica spectrum disorder
Radaelli, M.
Moiola, L.
Privitera, D.
Rodegher, M.
Colombo, B.
Barcella, V.
Sangalli, F.
Esposito, F.
Comi, G.
Martinelli, V.
[J]. JOURNAL OF NEUROLOGY, 2011, 258 : 261 - 262
[7] Efficacy and safety of tocilizumab for the treatment of refractory Neuromyelitis optica
Dalla Costa, G.
Moiola, L.
Falcini, M.
Cocco, E.
Novi, G.
Inglese, M.
Malucchi, S.
Bertolotto, A.
Capobianco, M.
Uccelli, A.
Martinelli, V.
Comi, G.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 366 - 367
[8] An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica
Collongues, Nicolas
de Seze, Jerome
[J]. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2016, 9 (03) : 180 - 188
[9] Efficacy and safety of tocilizumab for the treatment of refractory neuromyelitis optica
Moiola, L.
Dalla Costa, G.
Sangalli, F.
Romeo, M.
Radaelli, M.
Falcini, M.
Capobianco, M.
Malucchi, S.
Comi, G.
Martinelli, V.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 56 - 56
[10] Efficacy and safety of tocilizumab for the treatment of refractory neuromyelitis optica
Costa, G. Dalla
Preziosa, P.
Sangalli, F.
Messina, M. J.
Romeo, M.
Merlini, A.
Rodegher, M.
Moiola, L.
Martinelli, V.
Comi, G.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 719 - 719

← 1 2 3 4 5 →